Status:
COMPLETED
Post-Operative Nausea And Vomiting Study In Female Patients
Lead Sponsor:
GlaxoSmithKline
Conditions:
Postoperative Nausea and Vomiting
Nausea and Vomiting, Postoperative
Eligibility:
FEMALE
18-55 years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.
Detailed Description
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50 mg or 150 mg) for Three Consecutive Day...
Eligibility Criteria
Inclusion
- Known, specified risk factors for PONV (post operative nausea and vomiting)
- Undergoing gynecologic or gallbladder surgery.
Exclusion
- pregnant or breastfeeding
- post-menopausal
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
435 Patients enrolled
Trial Details
Trial ID
NCT00274690
Start Date
February 1 2005
End Date
August 1 2005
Last Update
January 20 2017
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
San Francisco, California, United States, 94115
2
GSK Investigational Site
Melbourne, Florida, United States, 32901
3
GSK Investigational Site
West Palm Beach, Florida, United States, 33409
4
GSK Investigational Site
Chicago, Illinois, United States, 60637